Literature DB >> 17058146

Disseminated necrotizing leukoencephalopathy following chemoradiation therapy for acute lymphoblastic leukemia.

Ajaya R Pande1, Kumiko Ando, Reiichi Ishikura, Yuki Nagami, Masayo Ogawa, Norihiko Kamikonya, Yumi Kaneda, Takakuni Tanizawa, Norio Nakao.   

Abstract

Disseminated necrotizing leukoencephalopathy (DNL) is a potentially fatal complication of treatment involving intrathecal administration of chemotherapeutic agents such as methotrexate (MTX) alone or in combination with cranial radiotherapy (RT). We describe a case of acute lymphoblastic leukemia (ALL) treated with high-dose intravenous and intrathecal methotrexate combined with craniospinal RT resulting in DNL. Typical MR imaging features of progressive deep white matter lesions showing a characteristic pattern of enhancement after contrast was seen in this case. Deep white matter lesions with ring-like enhancement and calcifications were seen on CT; it showed a mass effect at one stage, which is not typical for DNL. Long-term clinical and imaging follow-up were helpful for the diagnosis in this case.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17058146     DOI: 10.1007/s11604-006-0059-5

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  14 in total

Review 1.  Atypical MRI findings in treatment-related leukoencephalopathy: case report.

Authors:  Y Ohmoto; K Kajiwara; S Kato; T Nisizaki; H Ito; S Tamura
Journal:  Neuroradiology       Date:  1996-02       Impact factor: 2.804

2.  Treatment-related disseminated necrotizing leukoencephalopathy with characteristic contrast enhancement of the white matter.

Authors:  S N Laxmi; S Takahashi; K Matsumoto; S Higano; N Kurihara; M Imaizumi; K Abe; Y Itoyama; K Sakamoto
Journal:  Radiat Med       Date:  1996 Nov-Dec

3.  Transient encephalopathy after intrathekal methotrexate chemotherapy: diffusion-weighted MRI.

Authors:  W Küker; P Bader; U Herrlinger; S Heckl; T Nägele
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

4.  Pure methotrexate encephalopathy presenting with seizures: CT and MRI features.

Authors:  K Lövblad; P Kelkar; C Ozdoba; G Ramelli; L Remonda; G Schroth
Journal:  Pediatr Radiol       Date:  1998-02

5.  Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics.

Authors:  A W Bleyer
Journal:  Cancer Treat Rep       Date:  1977-11

6.  Disseminated necrotizing leukoencephalopathy following irradiation and methotrexate therapy for central nervous system infiltration of leukemia and lymphoma.

Authors:  H Sakamaki; Y Onozawa; Y Yano; K Imai; T Sasaki; T Ibuka; N Funada; T Matsuda
Journal:  Radiat Med       Date:  1993 Jul-Aug

7.  Vascular changes of methotrexate-related disseminated necrotizing leukoencephalopathy.

Authors:  K Suzuki; T Takemura; R Okeda; S Hatakeyama
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

8.  Calcified cerebral necrosis following ALL therapy.

Authors:  K M Müller; R Menne; K D Bachmann; H Gröbe
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

9.  Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma.

Authors:  L J Rubinstein; M M Herman; T F Long; J R Wilbur
Journal:  Cancer       Date:  1975-02       Impact factor: 6.860

10.  [Disseminated necrotizing leukoencephalopathy accompanied with multiple calcium deposits following antineoplastic and radiation therapy in a case of intracranial germ cell tumor: computerized tomographical study].

Authors:  T Shimura; S Nakazawa; Y Akutsu; M Matsumoto; M Kuzuhara; D Yoshida
Journal:  No Shinkei Geka       Date:  1989-06
View more
  2 in total

Review 1.  The central nervous system complications of bone marrow transplantation in children.

Authors:  Shoko Yoshida; Katsumi Hayakawa; Akira Yamamoto; Hiroshi Kuroda; Shinsaku Imashuku
Journal:  Eur Radiol       Date:  2008-05-20       Impact factor: 5.315

Review 2.  Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.

Authors:  Cristina Guarnera; Placido Bramanti; Emanuela Mazzon
Journal:  Ther Clin Risk Manag       Date:  2017-07-14       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.